Neurocrine Biosciences Stock Price, News & Analysis (NASDAQ:NBIX)

$70.49 0.07 (0.10 %)
(As of 12/15/2017 04:00 PM ET)
Previous Close$70.49
Today's Range$69.53 - $71.54
52-Week Range$37.35 - $75.98
Volume2.24 million shs
Average Volume730,032 shs
Market Capitalization$6.23 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.36

About Neurocrine Biosciences (NASDAQ:NBIX)

Neurocrine Biosciences logoNeurocrine Biosciences, Inc. is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson's disease. Its product pipeline also includes NBI-640756, which targets tremor and NBI-74788, which targets classic congenital adrenal hyperplasia. Its R&D focus is on addressing diseases and disorders of the central nervous and endocrine systems.

Receive NBIX News and Ratings via Email

Sign-up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:NBIX
CUSIP64125C10
Phone858-617-7600

Debt

Debt-to-Equity Ratio1.05%
Current Ratio14.38%
Quick Ratio14.37%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$15 million
Price / Sales415.84
Cash FlowN/A
Price / CashN/A
Book Value$3.62 per share
Price / Book19.47

Profitability

Trailing EPS($2.22)
Net Income$-141,090,000.00
Net MarginsN/A
Return on Equity-61.88%
Return on Assets-35.60%

Miscellaneous

Employees196
Outstanding Shares88,490,000

Neurocrine Biosciences (NASDAQ:NBIX) Frequently Asked Questions

What is Neurocrine Biosciences' stock symbol?

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

How were Neurocrine Biosciences' earnings last quarter?

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced its quarterly earnings data on Wednesday, November, 1st. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.36. The company had revenue of $60.77 million for the quarter, compared to analyst estimates of $29.38 million. During the same quarter in the prior year, the company posted ($0.43) EPS. View Neurocrine Biosciences' Earnings History.

When will Neurocrine Biosciences make its next earnings announcement?

Neurocrine Biosciences is scheduled to release their next quarterly earnings announcement on Monday, February, 12th 2018. View Earnings Estimates for Neurocrine Biosciences.

Where is Neurocrine Biosciences' stock going? Where will Neurocrine Biosciences' stock price be in 2017?

17 analysts have issued 1-year price objectives for Neurocrine Biosciences' stock. Their predictions range from $55.00 to $109.00. On average, they expect Neurocrine Biosciences' share price to reach $78.88 in the next twelve months. View Analyst Ratings for Neurocrine Biosciences.

What are Wall Street analysts saying about Neurocrine Biosciences stock?

Here are some recent quotes from research analysts about Neurocrine Biosciences stock:

  • 1. Needham & Company LLC analysts commented, "Neurocrine reported 3Q17 financial results yesterday. Ingrezza 3Q17 sales were $45.8M, well above our $20.0M and consensus $11M ests. Mgmt noted growth in TRX from 745 in 2Q17 to 5100 in 3Q17. We are raising our near-term and long-term sales ests significantly. Our 4Q17 Ingrezza sales estimate is $55.0M (was $15.0M). Mgmt highlighted possible challenges in 4Q17, including new competitor Austedo and essentially a reduction in price w/ introduction of 80mg capsule. Nevertheless, we believe our ests may still be conservative. Our new $86 price target (was $58) is 25x our $4.72 2020 EPS est, disc 15% annually." (11/2/2017)
  • 2. Cowen Inc analysts commented, "NBIX remains well funded, ending Q4 with $352MM in cash." (2/15/2017)
  • 3. Robert W. Baird analysts commented, "No change to outlook heading into Ingrezza approval. Neurocrine reported a solid end to the year, modestly beating estimates on lower-than-expected opex. Though we are only a few weeks into 2017, it has already been a busy year for NBIX. Expect the year to continue to bring multiple updates, from potential approval of Ingrezza in TD and Tourette data in May to Phase 3 UF data for elagolix near year-end, an elagolix NDA submission, advances in CAH and essential tremor, and FDA discussions on newly licensed opicapone' Earnings and spend in-line, expect accelerations into launch. 4Q16 EPS of ($0.51) modestly beat our/consensus estimates of ($0.54)/($0.57), respectively, due to lower than projected operating expenses. Looking ahead to 2017, management expects opex to increase to about $230M-$240M due activities surrounding the launch of Ingrezza." (2/15/2017)
  • 4. HC Wainwright analysts commented, "We expect FDA to agree in early 2017 that Atara has demonstrated comparability between clinical batches of ATA-129, or EBV-CTL, and the prior material produced at MSKCC, paving the way for Phase 3 start. We believe comparability data will include the number of cells to administer, cytoreactivity, cell storage time, restriction studies (HLA types), variability based on release criteria, and the methods by which data are collected. CMC amendment standard for new clinical material Importantly, a CMC amendment is standard practice for an IND when new clinical material is introduced; therefore, we view Atara’s process as normal." (1/18/2017)
  • 5. Jefferies Group LLC analysts commented, "While the study showed a stat sig improvement on the Clinical Global Impression of Change scale (CGI; p=0.015), the study did not reach stat sig on the 1EP of Yale Global Tic Severity Scale (YGTSS; p=0.18). No further trial details were released. Although a setback, we note that this does not directly read through to the pediatric study readout expected in April." (1/18/2017)

Who are some of Neurocrine Biosciences' key competitors?

Who are Neurocrine Biosciences' key executives?

Neurocrine Biosciences' management team includes the folowing people:

  • William H. Rastetter Ph.D., Independent Chairman of the Board (Age 68)
  • Kevin C. Gorman Ph.D., Chief Executive Officer, Director (Age 58)
  • Matt Abernethy, Chief Financial Officer (Age 38)
  • Eric S. Benevich, Chief Commercial Officer (Age 51)
  • Haig P. Bozigian Ph.D., Chief Development Officer (Age 59)
  • Julie Cooke, Chief People Officer
  • Kyle Gano Ph.D., Chief Business Development Officer (Age 44)
  • Dimitri E. Grigoriadis Ph.D., Chief Research Officer (Age 59)
  • Malcolm Lloyd-Smith, Chief Regulatory Officer (Age 61)
  • Christopher F. O'Brien M.D., Chief Medical Officer (Age 60)

Who owns Neurocrine Biosciences stock?

Neurocrine Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Janus Henderson Group PLC (6.22%), Perceptive Advisors LLC (5.41%), TimesSquare Capital Management LLC (2.65%), Bank of New York Mellon Corp (2.07%), Pictet Asset Management Ltd. (1.53%) and Wells Fargo & Company MN (1.07%). Company insiders that own Neurocrine Biosciences stock include Christopher Flint Obrien, Corinne H Nevinny, Darin Lippoldt, Dimitri E Grigoriadis, Gary A Lyons, Haig P Bozigian, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Richard F Pops, Timothy P Coughlin and William H Rastetter. View Institutional Ownership Trends for Neurocrine Biosciences.

Who sold Neurocrine Biosciences stock? Who is selling Neurocrine Biosciences stock?

Neurocrine Biosciences' stock was sold by a variety of institutional investors in the last quarter, including Westfield Capital Management Co. LP, Bank of New York Mellon Corp, Point72 Asset Management L.P., Artal Group S.A., Candriam Luxembourg S.C.A., JPMorgan Chase & Co., California State Teachers Retirement System and Neuberger Berman Group LLC. Company insiders that have sold Neurocrine Biosciences company stock in the last year include Christopher Flint Obrien, Corinne H Nevinny, Darin Lippoldt, Dimitri E Grigoriadis, Gary A Lyons, Haig P Bozigian, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Timothy P Coughlin and William H Rastetter. View Insider Buying and Selling for Neurocrine Biosciences.

Who bought Neurocrine Biosciences stock? Who is buying Neurocrine Biosciences stock?

Neurocrine Biosciences' stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Pictet Asset Management Ltd., First Trust Advisors LP, Janus Henderson Group PLC, Wells Fargo & Company MN, Dupont Capital Management Corp, AXA and Van ECK Associates Corp. View Insider Buying and Selling for Neurocrine Biosciences.

How do I buy Neurocrine Biosciences stock?

Shares of Neurocrine Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Neurocrine Biosciences' stock price today?

One share of Neurocrine Biosciences stock can currently be purchased for approximately $70.49.

How big of a company is Neurocrine Biosciences?

Neurocrine Biosciences has a market capitalization of $6.23 billion and generates $15 million in revenue each year. The company earns $-141,090,000.00 in net income (profit) each year or ($2.22) on an earnings per share basis. Neurocrine Biosciences employs 196 workers across the globe.

How can I contact Neurocrine Biosciences?

Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The company can be reached via phone at 858-617-7600 or via email at [email protected]


MarketBeat Community Rating for Neurocrine Biosciences (NBIX)

Community Ranking:  4.2 out of 5 (star star star star)
Outperform Votes:  575 (Vote Outperform)
Underperform Votes:  102 (Vote Underperform)
Total Votes:  677
MarketBeat's community ratings are surveys of what our community members think about Neurocrine Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Neurocrine Biosciences (NASDAQ:NBIX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.002.942.94
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
17 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
17 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
16 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
16 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $78.88$78.88$68.25$67.69
Price Target Upside: 12.50% upside5.67% upside20.35% upside46.45% upside

Neurocrine Biosciences (NASDAQ:NBIX) Consensus Price Target History

Price Target History for Neurocrine Biosciences (NASDAQ:NBIX)

Neurocrine Biosciences (NASDAQ:NBIX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/12/2017OppenheimerSet Price TargetBuy$85.00LowView Rating Details
11/3/2017Robert W. BairdReiterated RatingBuy$84.00N/AView Rating Details
11/2/2017Needham & Company LLCReiterated RatingBuy$86.00N/AView Rating Details
11/2/2017BarclaysBoost Price TargetOverweight$75.00 -> $85.00N/AView Rating Details
11/2/2017Deutsche BankReiterated RatingBuy$79.00N/AView Rating Details
11/2/2017BMO Capital MarketsBoost Price TargetPositive -> Outperform$83.00 -> $109.00N/AView Rating Details
11/2/2017Leerink SwannReiterated RatingOutperform$72.00 -> $83.00N/AView Rating Details
11/2/2017CitigroupReiterated RatingBuy$79.00N/AView Rating Details
10/25/2017Piper Jaffray CompaniesReiterated RatingBuy$76.00N/AView Rating Details
10/3/2017Jefferies GroupReiterated RatingBuy$66.00 -> $69.00LowView Rating Details
8/9/2017CowenReiterated RatingOutperform$60.00 -> $65.00MediumView Rating Details
5/24/2017J P Morgan Chase & CoSet Price TargetBuy$57.00MediumView Rating Details
5/15/2017Bank of AmericaReiterated RatingBuy$70.00MediumView Rating Details
3/7/2017Cantor FitzgeraldReiterated RatingOverweight$80.00N/AView Rating Details
2/16/2017HC WainwrightBoost Price TargetPositive$80.00 -> $100.00N/AView Rating Details
2/10/2017ICAPReiterated RatingOutperform$55.00N/AView Rating Details
1/27/2017CIBCUpgradeMarket Perform -> OutperformN/AView Rating Details
(Data available from 12/16/2015 forward)

Earnings

Neurocrine Biosciences (NASDAQ:NBIX) Earnings History and Estimates Chart

Earnings by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Neurocrine Biosciences (NASDAQ NBIX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/12/2018($0.10)N/AView Earnings Details
11/1/2017Q3 2017($0.49)($0.13)$29.38 million$60.77 millionViewN/AView Earnings Details
8/3/2017Q2 17($0.67)($0.68)$0.61 million$6.34 millionViewListenView Earnings Details
5/9/2017Q1 17($0.67)($0.90)$3.00 millionViewListenView Earnings Details
2/14/2017Q416($0.55)($0.51)$4.55 millionViewListenView Earnings Details
11/2/2016Q316($0.57)($0.43)ViewN/AView Earnings Details
5/5/2016Q1($0.29)($0.22)$15.43 million$15.00 millionViewN/AView Earnings Details
2/11/2016Q415($0.32)($0.34)$3.33 millionViewListenView Earnings Details
10/29/2015Q315($0.25)($0.40)$6.66 millionViewListenView Earnings Details
7/29/2015Q2($0.29)($0.28)$0.41 millionViewListenView Earnings Details
4/30/2015Q115($0.30)($0.01)$19.76 millionViewN/AView Earnings Details
2/9/2015Q414($0.24)($0.26)ViewN/AView Earnings Details
11/3/2014Q314($0.21)($0.21)ViewN/AView Earnings Details
8/6/2014Q214($0.18)($0.18)$0.12 millionViewN/AView Earnings Details
4/30/2014Q114($0.19)($0.17)$0.78 millionViewN/AView Earnings Details
2/6/2014Q413($0.17)($0.16)$0.79 million$0.73 millionViewN/AView Earnings Details
10/29/2013Q313($0.20)($0.17)$0.79 million$0.73 millionViewN/AView Earnings Details
7/25/2013Q2 2013($0.20)($0.18)$0.77 million$0.73 millionViewListenView Earnings Details
5/2/2013Q1 2013($0.18)($0.18)$1.07 million$0.70 millionViewListenView Earnings Details
2/8/2013Q4 2012($0.08)$0.14$9.43 million$21.90 millionViewListenView Earnings Details
10/31/2012Q312($0.05)($0.05)$10.28 million$9.40 millionViewN/AView Earnings Details
7/31/2012($0.03)($0.01)ViewN/AView Earnings Details
5/2/2012($0.01)ViewN/AView Earnings Details
10/31/2011$0.19$0.56ViewN/AView Earnings Details
7/28/2011$0.04$0.04ViewN/AView Earnings Details
5/3/2011$0.05$0.05ViewN/AView Earnings Details
2/10/2011$0.04$0.05ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Neurocrine Biosciences (NASDAQ:NBIX) Earnings Estimates

2017 EPS Consensus Estimate: ($1.86)
2018 EPS Consensus Estimate: ($0.82)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($0.89)($0.54)($0.65)
Q2 20174($0.68)($0.61)($0.65)
Q3 20174($0.72)($0.28)($0.53)
Q4 20174($0.21)$0.11($0.03)
Q1 20181($0.30)($0.30)($0.30)
Q2 20181($0.29)($0.29)($0.29)
Q3 20181($0.04)($0.04)($0.04)
Q4 20181($0.19)($0.19)($0.19)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Neurocrine Biosciences (NASDAQ:NBIX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Neurocrine Biosciences (NASDAQ NBIX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.80%
Insider Trades by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)
Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Neurocrine Biosciences (NASDAQ NBIX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/8/2017Darin LippoldtInsiderSell2,955$75.00$221,625.00View SEC Filing  
12/4/2017Darin LippoldtInsiderSell6,279$75.04$471,176.16View SEC Filing  
12/1/2017Gary A LyonsDirectorSell10,000$72.92$729,200.00View SEC Filing  
11/15/2017Darin LippoldtInsiderSell9,900$73.05$723,195.00View SEC Filing  
11/8/2017Dimitri E GrigoriadisInsiderSell30,000$74.58$2,237,400.00View SEC Filing  
11/2/2017Kyle GanoInsiderSell24,818$71.05$1,763,318.90View SEC Filing  
10/2/2017Christopher Flint ObrienInsiderSell6,925$61.04$422,702.00View SEC Filing  
9/6/2017Haig P BozigianInsiderSell26,250$60.00$1,575,000.00View SEC Filing  
9/5/2017Christopher Flint ObrienInsiderSell52,817$57.50$3,036,977.50View SEC Filing  
8/9/2017Dimitri E GrigoriadisInsiderSell15,354$55.00$844,470.00View SEC Filing  
8/4/2017Haig P BozigianInsiderSell22,500$50.00$1,125,000.00View SEC Filing  
7/27/2017Christopher Flint ObrienInsiderSell8,734$50.00$436,700.00View SEC Filing  
5/23/2017Dimitri E GrigoriadisInsiderSell10,000$53.39$533,900.00View SEC Filing  
5/19/2017Malcolm Lloyd-SmithInsiderSell9,960$53.63$534,154.80View SEC Filing  
5/5/2017Corinne H NevinnyDirectorSell5,000$53.98$269,900.00View SEC Filing  
5/2/2017Dimitri E GrigoriadisInsiderSell10,000$55.00$550,000.00View SEC Filing  
5/2/2017Kevin Charles GormanCEOSell21,739$53.23$1,157,166.97View SEC Filing  
5/1/2017Kyle GanoInsiderSell15,000$54.00$810,000.00View SEC Filing  
4/12/2017Haig P BozigianInsiderSell13,065$50.42$658,737.30View SEC Filing  
4/12/2017Kevin Charles GormanCEOSell19,596$50.42$988,030.32View SEC Filing  
2/7/2017Malcolm Lloyd-SmithInsiderSell116$44.61$5,174.76View SEC Filing  
2/6/2017Dimitri E GrigoriadisInsiderSell727$43.13$31,355.51View SEC Filing  
2/6/2017Kevin Charles GormanCEOSell3,010$43.18$129,971.80View SEC Filing  
2/6/2017Timothy P CoughlinCFOSell963$43.14$41,543.82View SEC Filing  
2/3/2017Christopher Flint ObrienInsiderSell1,500$42.50$63,750.00View SEC Filing  
2/3/2017Kevin Charles GormanCEOSell3,125$42.55$132,968.75View SEC Filing  
2/1/2017William H RastetterDirectorSell10,750$42.28$454,510.00View SEC Filing  
1/17/2017Haig P BozigianInsiderSell1,625$40.63$66,023.75View SEC Filing  
1/17/2017Kevin Charles GormanCEOSell3,750$40.65$152,437.50View SEC Filing  
1/17/2017Timothy P CoughlinCFOSell1,750$40.65$71,137.50View SEC Filing  
1/10/2017Christopher Flint ObrienInsiderSell1,750$43.35$75,862.50View SEC Filing  
1/10/2017Kevin Charles GormanCEOSell3,750$43.28$162,300.00View SEC Filing  
11/15/2016Christopher Flint ObrienInsiderSell25,000$52.84$1,321,000.00View SEC Filing  
9/1/2016Malcolm Lloyd-SmithInsiderSell9,000$50.00$450,000.00View SEC Filing  
8/15/2016Christopher Flint ObrienInsiderSell12,500$48.73$609,125.00View SEC Filing  
8/8/2016Corinne H NevinnyDirectorSell5,000$48.54$242,700.00View SEC Filing  
5/25/2016Richard F PopsDirectorSell15,000$46.72$700,800.00View SEC Filing  
5/16/2016Christopher Flint ObrienInsiderSell25,000$45.00$1,125,000.00View SEC Filing  
4/11/2016Kyle GanoInsiderSell41,770$44.02$1,838,715.40View SEC Filing  
4/6/2016Christopher Flint ObrienInsiderSell25,000$45.00$1,125,000.00View SEC Filing  
2/3/2016Haig P BozigianInsiderSell1,375$38.13$52,428.75View SEC Filing  
2/3/2016Kevin Charles GormanCEOSell3,125$38.04$118,875.00View SEC Filing  
2/3/2016Timothy P CoughlinCFOSell1,500$38.06$57,090.00View SEC Filing  
1/19/2016Haig P BozigianInsiderSell1,625$46.77$76,001.25View SEC Filing  
1/19/2016Kevin Charles GormanCEOSell3,750$46.70$175,125.00View SEC Filing  
1/19/2016Timothy P CoughlinCFOSell1,750$46.69$81,707.50View SEC Filing  
1/11/2016Haig P BozigianInsiderSell1,625$44.25$71,906.25View SEC Filing  
1/11/2016Kevin Charles GormanCEOSell3,750$44.17$165,637.50View SEC Filing  
1/11/2016Timothy P CoughlinCFOSell1,750$44.25$77,437.50View SEC Filing  
11/27/2015Dimitri E. GrigoriadisinsiderSell10,000$57.50$575,000.00View SEC Filing  
11/9/2015Darin LippoldtinsiderSell23,761$52.92$1,257,432.12View SEC Filing  
10/16/2015Haig P BozigianInsiderSell25,000$47.78$1,194,500.00View SEC Filing  
10/16/2015Kevin Charles GormanCEOSell33,500$47.77$1,600,295.00View SEC Filing  
9/18/2015Gary A. LyonsDirectorSell15,000$54.89$823,350.00View SEC Filing  
7/20/2015Dimitri E GrigoriadisInsiderSell19,646$55.00$1,080,530.00View SEC Filing  
7/20/2015Timothy P CoughlinCFOSell20,000$55.00$1,100,000.00View SEC Filing  
7/13/2015Dimitri E GrigoriadisInsiderSell10,000$50.00$500,000.00View SEC Filing  
7/13/2015Timothy P CoughlinCFOSell20,000$50.00$1,000,000.00View SEC Filing  
6/23/2015W Thomas MitchellDirectorSell15,000$49.35$740,250.00View SEC Filing  
6/8/2015Christopher Flint ObrienInsiderSell10,000$45.00$450,000.00View SEC Filing  
6/8/2015Timothy P CoughlinCFOSell60,000$45.08$2,704,800.00View SEC Filing  
3/24/2015Gary A LyonsDirectorSell30,000$41.53$1,245,900.00View SEC Filing  
3/24/2015Kevin Charles GormanCEOSell40,000$41.53$1,661,200.00View SEC Filing  
2/10/2015Dimitri E GrigoriadisInsiderSell20,000$35.00$700,000.00View SEC Filing  
1/16/2015Christopher Flint ObrienInsiderSell1,750$30.79$53,882.50View SEC Filing  
1/16/2015Kevin Charles GormanCEOSell3,750$30.79$115,462.50View SEC Filing  
1/12/2015Kevin Charles GormanCEOSell3,750$28.43$106,612.50View SEC Filing  
1/12/2015Kyle GanoInsiderSell1,250$28.41$35,512.50View SEC Filing  
1/12/2015Timothy P CoughlinCFOSell1,750$28.37$49,647.50View SEC Filing  
1/8/2015Dimitri E GrigoriadisInsiderSell30,000$27.35$820,500.00View SEC Filing  
1/8/2015Kevin Charles GormanCEOSell25,000$27.39$684,750.00View SEC Filing  
1/8/2015Timothy P CoughlinCFOSell10,000$27.25$272,500.00View SEC Filing  
1/5/2015Dimitri E GrigoriadisInsiderSell2,500$22.76$56,900.00View SEC Filing  
1/2/2015W Thomas MitchellDirectorSell8,000$22.79$182,320.00View SEC Filing  
12/19/2014Christopher Flint ObrienInsiderSell20,000$24.02$480,400.00View SEC Filing  
12/19/2014Kevin Charles GormanCEOSell70,000$23.41$1,638,700.00View SEC Filing  
12/19/2014Timothy P CoughlinCFOSell30,000$23.46$703,800.00View SEC Filing  
12/17/2014Kyle GanoInsiderSell4,957$22.50$111,532.50View SEC Filing  
12/15/2014Dimitri E GrigoriadisInsiderSell12,794$22.35$285,945.90View SEC Filing  
12/12/2014Kyle GanoInsiderSell4,043$22.50$90,967.50View SEC Filing  
12/11/2014Christopher Flint ObrienInsiderSell40,000$21.82$872,800.00View SEC Filing  
12/10/2014Timothy P CoughlinCFOSell20,000$21.48$429,600.00View SEC Filing  
12/10/2014W Thomas MitchellDirectorSell7,000$21.90$153,300.00View SEC Filing  
11/28/2014Timothy P CoughlinCFOSell10,000$20.14$201,400.00View SEC Filing  
11/24/2014Christopher Flint ObrienInsiderSell5,463$19.53$106,692.39View SEC Filing  
10/31/2014Timothy P CoughlinCFOSell10,000$19.00$190,000.00View SEC Filing  
10/30/2014Timothy P CoughlinCFOSell20,000$18.31$366,200.00View SEC Filing  
10/1/2014W Thomas MitchellDirectorSell1,275$15.50$19,762.50View SEC Filing  
9/15/2014Gary A LyonsDirectorSell20,000$15.66$313,200.00View SEC Filing  
1/17/2014Dimitri GrigoriadisInsiderSell25,000$20.00$500,000.00View SEC Filing  
1/10/2014Christopher Flint ObrienInsiderSell6,750$18.88$127,440.00View SEC Filing  
1/10/2014Kevin Charles GormanCEOSell3,750$18.57$69,637.50View SEC Filing  
1/10/2014Timothy CoughlinCFOSell1,750$18.56$32,480.00View SEC Filing  
1/7/2014Dimitri GrigoriadisInsiderSell25,000$17.50$437,500.00View SEC Filing  
1/7/2014Kevin Charles GormanCEOSell108,000$16.76$1,810,080.00View SEC Filing  
1/7/2014Timothy CoughlinCFOSell70,000$16.75$1,172,500.00View SEC Filing  
9/4/2013Kyle GanoInsiderSell2,400$15.61$37,464.00View SEC Filing  
9/3/2013Christopher Flint ObrienInsiderSell5,000$16.00$80,000.00View SEC Filing  
8/21/2013Haig BozigianInsiderSell13,999$15.04$210,544.96View SEC Filing  
8/21/2013Timothy CoughlinCFOSell19,035$15.05$286,476.75View SEC Filing  
8/6/2013W Thomas MitchellDirectorSell1,531$14.70$22,505.70View SEC Filing  
8/5/2013Haig BozigianInsiderSell11,001$15.00$165,015.00View SEC Filing  
8/5/2013Timothy CoughlinCFOSell10,965$14.99$164,365.35View SEC Filing  
7/12/2013Christopher Flint ObrienInsiderSell5,000$14.50$72,500.00View SEC Filing  
6/28/2013Christopher Flint ObrienInsiderSell11,357$13.33$151,388.81View SEC Filing  
6/27/2013Haig P BozigianInsiderSell8,000$13.00$104,000.00View SEC Filing  
6/21/2013Dimitri E GrigoriadisInsiderSell46,837$12.51$585,930.87View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Neurocrine Biosciences (NASDAQ NBIX) News Headlines

Source:
DateHeadline
Neurocrine Biosciences, Inc. (NBIX) Insider Sells $221,625.00 in StockNeurocrine Biosciences, Inc. (NBIX) Insider Sells $221,625.00 in Stock
www.americanbankingnews.com - December 11 at 5:58 PM
Neurocrine Biosciences to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare ConferenceNeurocrine Biosciences to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference
finance.yahoo.com - December 7 at 5:19 PM
Insider Selling: Neurocrine Biosciences, Inc. (NBIX) Insider Sells 6,279 Shares of StockInsider Selling: Neurocrine Biosciences, Inc. (NBIX) Insider Sells 6,279 Shares of Stock
www.americanbankingnews.com - December 6 at 5:46 PM
Neurocrine Biosciences, Inc. (NBIX) Director Sells $729,200.00 in StockNeurocrine Biosciences, Inc. (NBIX) Director Sells $729,200.00 in Stock
www.americanbankingnews.com - December 5 at 6:20 PM
Neurocrine Biosciences (NBIX) Presents Long-term Data Analyses ... - StreetInsider.comNeurocrine Biosciences (NBIX) Presents Long-term Data Analyses ... - StreetInsider.com
www.streetinsider.com - December 5 at 10:36 AM
Neurocrine Biosciences Presents Long-term Data Analyses from Open-label KINECT 4 Phase III Study Demonstrating INGREZZA® Improves Tardive Dyskinesia SymptomsNeurocrine Biosciences Presents Long-term Data Analyses from Open-label KINECT 4 Phase III Study Demonstrating INGREZZA® Improves Tardive Dyskinesia Symptoms
finance.yahoo.com - December 4 at 4:57 PM
$75.70 Million in Sales Expected for Neurocrine Biosciences, Inc. (NBIX) This Quarter$75.70 Million in Sales Expected for Neurocrine Biosciences, Inc. (NBIX) This Quarter
www.americanbankingnews.com - December 2 at 8:08 AM
 Analysts Expect Neurocrine Biosciences, Inc. (NBIX) Will Post Earnings of -$0.03 Per Share Analysts Expect Neurocrine Biosciences, Inc. (NBIX) Will Post Earnings of -$0.03 Per Share
www.americanbankingnews.com - November 30 at 9:26 AM
Neurocrine Biosciences to Present New Long-Term Data Evaluating INGREZZA® for the Treatment of Tardive Dyskinesia at the American College of Neuropsychopharmacology Annual MeetingNeurocrine Biosciences to Present New Long-Term Data Evaluating INGREZZA® for the Treatment of Tardive Dyskinesia at the American College of Neuropsychopharmacology Annual Meeting
finance.yahoo.com - November 29 at 5:18 PM
Neurocrine Biosciences, Inc. (NBIX) Receives Average Recommendation of "Buy" from AnalystsNeurocrine Biosciences, Inc. (NBIX) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - November 26 at 1:38 AM
Neurocrine Biosciences to Present at the 29th Annual Piper Jaffray Healthcare Conference - PR Newswire (press release)Neurocrine Biosciences to Present at the 29th Annual Piper Jaffray Healthcare Conference - PR Newswire (press release)
www.prnewswire.com - November 23 at 5:23 PM
Neurocrine Biosciences to Present at the 29th Annual Piper Jaffray Healthcare ConferenceNeurocrine Biosciences to Present at the 29th Annual Piper Jaffray Healthcare Conference
finance.yahoo.com - November 22 at 6:05 AM
Neurocrine Biosciences (NBIX) Names Matt Abernethy as CFONeurocrine Biosciences (NBIX) Names Matt Abernethy as CFO
www.streetinsider.com - November 21 at 8:31 AM
Detailed Research: Economic Perspectives on Nexstar Broadcasting Group, CECO Environmental, Performance Food Group, Neurocrine Biosciences, e.l.f. Beauty, and Big Lots — What Drives Growth in Todays Competitive LandscapeDetailed Research: Economic Perspectives on Nexstar Broadcasting Group, CECO Environmental, Performance Food Group, Neurocrine Biosciences, e.l.f. Beauty, and Big Lots — What Drives Growth in Today's Competitive Landscape
finance.yahoo.com - November 21 at 8:31 AM
Neurocrine Biosciences Appoints Matt Abernethy as Chief Financial OfficerNeurocrine Biosciences Appoints Matt Abernethy as Chief Financial Officer
www.prnewswire.com - November 20 at 4:23 PM
Head to Head Survey: Neurocrine Biosciences (NBIX) and Its CompetitorsHead to Head Survey: Neurocrine Biosciences (NBIX) and Its Competitors
www.americanbankingnews.com - November 18 at 5:12 AM
Neurocrine Biosciences, Inc. (NBIX) Insider Sells $723,195.00 in StockNeurocrine Biosciences, Inc. (NBIX) Insider Sells $723,195.00 in Stock
www.americanbankingnews.com - November 17 at 8:11 PM
Head-To-Head Comparison: Neurocrine Biosciences (NBIX) vs. Its CompetitorsHead-To-Head Comparison: Neurocrine Biosciences (NBIX) vs. Its Competitors
www.americanbankingnews.com - November 17 at 8:36 AM
Neurocrine Announces Long-Term Results Evaluating INGREZZA® for the Treatment of Adults with Tardive Dyskinesia Published in the Journal of Clinical PsychiatryNeurocrine Announces Long-Term Results Evaluating INGREZZA® for the Treatment of Adults with Tardive Dyskinesia Published in the Journal of Clinical Psychiatry
finance.yahoo.com - November 14 at 3:34 PM
Neurocrine Biosciences, Inc. (NBIX) Given a $85.00 Price Target by Oppenheimer Holdings, Inc. AnalystsNeurocrine Biosciences, Inc. (NBIX) Given a $85.00 Price Target by Oppenheimer Holdings, Inc. Analysts
www.americanbankingnews.com - November 14 at 3:18 PM
Dimitri E. Grigoriadis Sells 30,000 Shares of Neurocrine Biosciences, Inc. (NBIX) StockDimitri E. Grigoriadis Sells 30,000 Shares of Neurocrine Biosciences, Inc. (NBIX) Stock
www.americanbankingnews.com - November 13 at 4:48 PM
Zacks: Analysts Expect Neurocrine Biosciences, Inc. (NBIX) Will Post Quarterly Sales of $75.70 MillionZacks: Analysts Expect Neurocrine Biosciences, Inc. (NBIX) Will Post Quarterly Sales of $75.70 Million
www.americanbankingnews.com - November 13 at 4:46 AM
INGREZZA®, First FDA Approved Product for the Treatment of Tardive Dyskinesia, Receives Outstanding Therapeutic Product Award from Prestigious California Life Sciences AssociationINGREZZA®, First FDA Approved Product for the Treatment of Tardive Dyskinesia, Receives Outstanding Therapeutic Product Award from Prestigious California Life Sciences Association
finance.yahoo.com - November 12 at 10:12 AM
 Analysts Expect Neurocrine Biosciences, Inc. (NBIX) to Announce -$0.03 EPS Analysts Expect Neurocrine Biosciences, Inc. (NBIX) to Announce -$0.03 EPS
www.americanbankingnews.com - November 11 at 11:24 PM
Neurocrine Biosciences to Present at the Jefferies 2017 London Healthcare ConferenceNeurocrine Biosciences to Present at the Jefferies 2017 London Healthcare Conference
finance.yahoo.com - November 9 at 7:17 AM
Neurocrine Biosciences, Inc. (NBIX) Insider Sells $1,763,318.90 in StockNeurocrine Biosciences, Inc. (NBIX) Insider Sells $1,763,318.90 in Stock
www.americanbankingnews.com - November 6 at 6:32 PM
FY2017 Earnings Estimate for Neurocrine Biosciences, Inc. (NBIX) Issued By Oppenheimer HoldingsFY2017 Earnings Estimate for Neurocrine Biosciences, Inc. (NBIX) Issued By Oppenheimer Holdings
www.americanbankingnews.com - November 6 at 4:14 AM
Brokers Set Expectations for Neurocrine Biosciences, Inc.s FY2017 Earnings (NBIX)Brokers Set Expectations for Neurocrine Biosciences, Inc.'s FY2017 Earnings (NBIX)
www.americanbankingnews.com - November 6 at 4:14 AM
FY2017 EPS Estimates for Neurocrine Biosciences, Inc. (NBIX) Boosted by Leerink SwannFY2017 EPS Estimates for Neurocrine Biosciences, Inc. (NBIX) Boosted by Leerink Swann
www.americanbankingnews.com - November 6 at 4:14 AM
Neurocrine Biosciences, Inc. Expected to Earn FY2017 Earnings of ($1.75) Per Share (NBIX)Neurocrine Biosciences, Inc. Expected to Earn FY2017 Earnings of ($1.75) Per Share (NBIX)
www.americanbankingnews.com - November 6 at 3:50 AM
Investors Purchase High Volume of Put Options on Neurocrine Biosciences (NBIX)Investors Purchase High Volume of Put Options on Neurocrine Biosciences (NBIX)
www.americanbankingnews.com - November 6 at 2:28 AM
Neurocrine Biosciences Inc. (NBIX) Has Jumped To A New High On Q3 ResultsNeurocrine Biosciences Inc. (NBIX) Has Jumped To A New High On Q3 Results
www.nasdaq.com - November 4 at 7:26 AM
Neurocrine Biosciences Inc. (NBIX) Leaped To A New High On Q3 ResultsNeurocrine Biosciences Inc. (NBIX) Leaped To A New High On Q3 Results
www.rttnews.com - November 4 at 7:26 AM
Here's Why Neurocrine Biosciences Is SoaringHere's Why Neurocrine Biosciences Is Soaring
finance.yahoo.com - November 4 at 7:25 AM
Neurocrine Biosciences Exceeds Expectations With Ingrezza LaunchNeurocrine Biosciences Exceeds Expectations With Ingrezza Launch
finance.yahoo.com - November 4 at 7:25 AM
Stocks Showing Market Leadership: Neurocrine Biosciences Earns 96 RS RatingStocks Showing Market Leadership: Neurocrine Biosciences Earns 96 RS Rating
finance.yahoo.com - November 4 at 7:25 AM
Neurocrine stock rockets to a record on sales beat—but can it last?Neurocrine stock rockets to a record on sales beat—but can it last?
finance.yahoo.com - November 4 at 7:25 AM
Neurocrine Biosciences (NBIX) "Buy" Rating Reiterated at Robert W. BairdNeurocrine Biosciences' (NBIX) "Buy" Rating Reiterated at Robert W. Baird
www.americanbankingnews.com - November 4 at 12:36 AM
Neurocrine Biosciences, Inc. (NBIX) Receives "Buy" Rating from Needham & Company LLCNeurocrine Biosciences, Inc. (NBIX) Receives "Buy" Rating from Needham & Company LLC
www.americanbankingnews.com - November 2 at 10:30 PM
Neurocrine Biosciences, Inc. (NBIX) PT Raised to $85.00 at Barclays PLCNeurocrine Biosciences, Inc. (NBIX) PT Raised to $85.00 at Barclays PLC
www.americanbankingnews.com - November 2 at 9:48 PM
Oppenheimer Holdings, Inc. Raises Neurocrine Biosciences, Inc. (NBIX) Price Target to $85.00Oppenheimer Holdings, Inc. Raises Neurocrine Biosciences, Inc. (NBIX) Price Target to $85.00
www.americanbankingnews.com - November 2 at 9:48 PM
Heres Why Neurocrine Biosciences Is SoaringHere's Why Neurocrine Biosciences Is Soaring
www.fool.com - November 2 at 1:42 PM
Neurocrine Biosciences, Inc. (NBIX) Price Target Raised to $109.00Neurocrine Biosciences, Inc. (NBIX) Price Target Raised to $109.00
www.americanbankingnews.com - November 2 at 11:02 AM
Neurocrine Biosciences, Inc. (NBIX) Stock Rating Reaffirmed by Leerink SwannNeurocrine Biosciences, Inc. (NBIX) Stock Rating Reaffirmed by Leerink Swann
www.americanbankingnews.com - November 2 at 11:02 AM
NBIX Delivers, MNTAs Biosimilar Drug Trial Fails, No FDA Panel Meet For RARE - NasdaqNBIX Delivers, MNTA's Biosimilar Drug Trial Fails, No FDA Panel Meet For RARE - Nasdaq
www.nasdaq.com - November 2 at 6:46 AM
Edited Transcript of NBIX earnings conference call or presentation 1-Nov-17 9:00pm GMTEdited Transcript of NBIX earnings conference call or presentation 1-Nov-17 9:00pm GMT
finance.yahoo.com - November 2 at 6:46 AM
Neurocrine Biosciences, Inc. (NBIX) Posts  Earnings Results, Beats Expectations By $0.36 EPSNeurocrine Biosciences, Inc. (NBIX) Posts Earnings Results, Beats Expectations By $0.36 EPS
www.americanbankingnews.com - November 1 at 7:44 PM
Neurocrine Biosciences to Present at the Credit Suisse 26th Annual Healthcare ConferenceNeurocrine Biosciences to Present at the Credit Suisse 26th Annual Healthcare Conference
finance.yahoo.com - November 1 at 6:40 AM
Neurocrine Biosciences, Inc. (NBIX) Receives Consensus Rating of "Buy" from AnalystsNeurocrine Biosciences, Inc. (NBIX) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - November 1 at 3:32 AM
Daily Technical Summary Reports on Generic Drugs Stocks -- Ironwood Pharma, Mylan, Neurocrine Biosciences, and ... - PR Newswire (press release)Daily Technical Summary Reports on Generic Drugs Stocks -- Ironwood Pharma, Mylan, Neurocrine Biosciences, and ... - PR Newswire (press release)
www.prnewswire.com - October 28 at 8:34 AM

SEC Filings

Neurocrine Biosciences (NASDAQ:NBIX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Neurocrine Biosciences (NASDAQ:NBIX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Neurocrine Biosciences (NASDAQ NBIX) Stock Chart for Saturday, December, 16, 2017

Loading chart…

This page was last updated on 12/16/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.